Condition: Secondary Progressive Multiple Sclerosis (SPMS) · Sponsor: Cairo University
The goal of this clinical trial is to know if rituximab can improve cognitive and hand functions in secondary progressive multiple sclerosis (SPMS) patients with high disability (EDSS 6.5 or more). The main questions it aims to answer are: Can rituximab improve cognitive and hand functions in SPMS patients? Can rituximab improve the quality of life and the Expanded Disability Status Scale (EDSS) in SPMS patients? Researchers will compare patients who receive rituximab to patient who receive placebo to see the effects of rituximab on cognition, hand functions, quality of life and EDSS. Demographic and clinical data as age, gender, disease duration and EDSS will be obtained from each participant. Participants will perform The Brief International Cognitive Assessment for Multiple Sclerosis (BICAMS), The Nine-Hole Peg Test (9-HPT) and The MS-QLQ27 questionnaire at baseline and after one year of receiving either rituximab or placebo.
This description comes directly from the study's public registry record.
Amgad Mahmoud Elmeligy, MSc Neurology · 00201005393868 · amgad.elmeligy92@outlook.com
Amr Mohamed Fouad, MD Neurology · 00201003598364 · amro.fouad@yahoo.com
Always discuss trial participation with your own doctor first.
| Kasr Alainy Multiple Sclerosis Unit (KAMSU), Cairo University hospitals. | Giza, Giza Governorate, Egypt | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT06599307